Unicycive Therapeutics UNCY Stock
0.65 USD
{{ price }}
1.343750%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqCM
Market Cap
77.64M USD
LOW - HIGH [24H]
0.63
-
0.66 USD
VOLUME [24H]
232.77K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.56 USD
Unicycive Therapeutics Price Chart
Unicycive Therapeutics UNCY Financial and Trading Overview
| Unicycive Therapeutics stock price | 0.65 USD |
| Previous Close | 1.6 USD |
| Open | 1.59 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1800 |
| Day's Range | 1.53 - 1.63 USD |
| 52 Week Range | 0.4 - 2.87 USD |
| Volume | 120.78K USD |
| Avg. Volume | 377.36K USD |
| Market Cap | 24.07M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.4 USD |
UNCY Valuation Measures
| Enterprise Value | 26.63M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.77193 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.802832 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 16.379 |
| Enterprise Value/EBITDA | -1.423 |
Trading Information
Unicycive Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 64.58% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.87 USD |
| 52 Week Low | 0.4 USD |
| 50-Day Moving Average | 1.54 USD |
| 200-Day Moving Average | 1.01 USD |
UNCY Share Statistics
| Avg. Volume (3 month) | 377.36K USD |
| Avg. Daily Volume (10-Days) | 201.69K USD |
| Shares Outstanding | 15.23M |
| Float | 5.94M |
| Short Ratio | 1.09 |
| % Held by Insiders | 41.27% |
| % Held by Institutions | 18.19% |
| Shares Short | 252.02K |
| Short % of Float | 2.77% |
| Short % of Shares Outstanding | 1.65% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1151.10% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -54.45% |
| Return on Equity (ttm) | -244.90% |
Income Statement
| Revenue (ttm) | 1.63M USD |
| Revenue Per Share (ttm) | 0.11 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -18710000 USD |
| Net Income Avi to Common (ttm) | -29288000 USD |
| Diluted EPS (ttm) | -1.81 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 24.33M USD |
| Total Cash Per Share (mrq) | 1.6 USD |
| Total Debt (mrq) | 991K USD |
| Total Debt/Equity (mrq) | 9.42 USD |
| Current Ratio (mrq) | 1.64 |
| Book Value Per Share (mrq) | -0.99 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16614000 USD |
| Levered Free Cash Flow (ttm) | 2.8M USD |
Profile of Unicycive Therapeutics
| Country | United States |
| State | CA |
| City | Los Altos |
| Address | 4300 El Camino Real |
| ZIP | 94022 |
| Phone | (650) 351-4495 |
| Website | https://unicycive.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Q&A For Unicycive Therapeutics Stock
What is a current UNCY stock price?
Unicycive Therapeutics UNCY stock price today per share is 0.65 USD.
How to purchase Unicycive Therapeutics stock?
You can buy UNCY shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Unicycive Therapeutics?
The stock symbol or ticker of Unicycive Therapeutics is UNCY.
Which industry does the Unicycive Therapeutics company belong to?
The Unicycive Therapeutics industry is Biotechnology.
How many shares does Unicycive Therapeutics have in circulation?
The max supply of Unicycive Therapeutics shares is 119.71M.
What is Unicycive Therapeutics Price to Earnings Ratio (PE Ratio)?
Unicycive Therapeutics PE Ratio is now.
What was Unicycive Therapeutics earnings per share over the trailing 12 months (TTM)?
Unicycive Therapeutics EPS is -0.56 USD over the trailing 12 months.
Which sector does the Unicycive Therapeutics company belong to?
The Unicycive Therapeutics sector is Healthcare.
Unicycive Therapeutics UNCY included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.56B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.56B USD — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
- {{ link.label }} {{link}}